Abivax (ABVX) Accounts Payables (2022 - 2026)

Abivax's Accounts Payables history runs 5 years deep, the most recent figure standing at $34.6 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 41.89% year-over-year to $34.6 million; the TTM figure through Mar 2026 stood at $34.6 million (down 41.89% YoY), while the FY2025 annual figure was $43.7 million, down 6.66% from the prior year.
• Accounts Payables was $34.6 million for Q1 2026 at Abivax, down from $43.7 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $65.1 million in Q2 2025 to a low of $15.8 million in Q4 2022.
• Historically, Accounts Payables has averaged $42.8 million across 5 years, with a median of $43.7 million in 2025.
• The sharpest annual moves came in 2023 and 2026: Accounts Payables surged 221.8% in 2023, then plunged 41.89% in 2026.
• A 5-year view of Accounts Payables shows it stood at $15.8 million in 2022, then soared by 221.8% to $50.8 million in 2023, then decreased by 7.83% to $46.8 million in 2024, then dropped by 6.66% to $43.7 million in 2025, then declined by 20.95% to $34.6 million in 2026.
• The last three Accounts Payables figures came in at $34.6 million (Q1 2026), $43.7 million (Q4 2025), and $35.1 million (Q3 2025), per Business Quant data.